Capital Resource Alliance, Inc. (OTCPINK: CRRA) saw its share volume skyrocket on May 16th with 6,914,728 shares exchanging hands, four times higher than its three month daily average volume of 1,664,413 shares.
Capital Resource Alliance announced it has completed the acquisition of Nate’s Pancakes, Inc. As part of the acquisition Nate’s Pancakes is a wholly owned subsidiary of the Company (the "Merger"). As part of the acquisition, Capital Resources Alliance issued Preferred Stock to the shareholders of Nate’s Pancakes. No common stock will be issued in exchange for the acquisition of Nate’s Pancakes. The Company will provide an additional update on the production schedule for Nate’s Pancakes in the 2 weeks.
Nate’s Pancakes make ready-to-use, pre-mixed pancake and waffle batter delivered in a pressurized shelf stable can. Our pre-made batter makes light and airy pancakes or waffles that are fun for the entire family to make together, and are a great way to start your day. Nate Steck, who also created Batter Blaster, created Nate’s Pancakes.
CRRA closed the day at $.062, 44.19% higher than its previous close of $.043.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
Amarantus Bioscience Holdings’s President To Speak At Investor Conference
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) saw its share volume soar on May 16th with 8,198,102 shares exchanging hands, higher than its three month daily average volume of 5,761,209 shares.
This uptick in volume comes after Amarantus Bioscience Holdings, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that Gerald E. Commissiong, President and CEO will be presenting at the 15th Annual B. Riley & Co. Investor Conference in Santa Monica, CA.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").
AMBS closed at $.0825 on May 16th, 7.14% higher than its previous close of $.077.
Terra Tech Corp. Releases First Quarter Financial Results
Terra Tech Corp. (OTCQB: TRTC) saw its share volume decline on May 16th with 2,815,202 shares exchanging hands, almost half of its three month daily average volume of 5,162,970 shares.
Terra Tech Corp. released its first quarter 2014 financial report. Total revenues generated from the sales of the Company's products for the quarter ended March 31, 2014 totaled $560,319, an increase of $494,198 from the quarter ended March 31, 2013, which totaled $66,121. The net result for the quarter ended March 31, 2014 was a loss of .03 cents per share compared to a loss of $.02 cents per share for the quarter ended March 31, 2013. The increase in loss per share was primarily associated with a non-cash loss on the fair market valuation of derivatives associated with the company's financings throughout the quarter. The company finished the quarter with a strong cash position of over $2.9 Million.
TRTC closed at $.445 on May 16th, 11% down from its previous close of $.50.
Stevia Corp. Achieves Projection
Stevia Corp. (OTCQB: STEV) saw its share volume continue its upward trend on May 16th with 3,514,968 shares exchanging hands, higher than its three month daily average volume of 2,866,522 shares.
This uptick in volume comes after Stevia Corp. announced it achieved its projection for the current harvest and is now in talks to supply a major Fortune 500 company.
Stevia Corp. harvested more than 2,000 tons of crops during the spring harvest of 2014, doubling the 2013 spring harvest. The majority of the spring harvest occurred during the Company's fourth quarter ending March 31, 2014 with the balance occurring during the current quarter ending June 30, 2014.
George Blankenbaker, Stevia Corp President, comments, "We are continuing to diversify our crop portfolio and add international clients. To date, we are working with the largest food conglomerate in South Korea, a major importer to Europe, and we are in talks with a major Fortune 500 company to supply its South East Asian operations. Our model is working, now it is a matter of scaling it."
Mr. Blankenbaker continues, "With our production base firmly in place, we are focused on developing the US market and increasing our margins with higher value added products. Real Hemp LLC, our US subsidiary, will play a central role in this effort. We are currently confirming final details of our initial products for the US market with the intent to go live with our Real Hemp website in June 2014."
STEV closed the day at $.144 on May 16th, 14.69% lower than its previous close of $.1688.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.